Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS for Microvascular Perfusion in Pediatric COVID-19
NCT04640038Phase 3Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sulfur hexafluoride in coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome (MIS), sponsored by Children's Hospital of Philadelphia. Primary endpoint: Proportion of Patients With Normal Perfusion Versus Area(s) of Hypoperfusion at 15 minutes. Started Dec 2020; status: completed.
02
Drugs
sulfur hexafluoride
03
Conditions
coronavirus disease 2019 (COVID-19)multisystem inflammatory syndrome (MIS)
Beyond the preview
Go deeper on NCT04640038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640038.